Lineage Cell Therapeutics (LCTX) Convertible Debt (2014 - 2017)

Lineage Cell Therapeutics has reported Convertible Debt for 4 years, with the latest figure at $1.9 million in Q4 2017.

• For the quarter ending Q4 2017, Convertible Debt rose 80.72% year-over-year to $1.9 million; the trailing twelve-month figure through Dec 2017 stood at $1.9 million (up 80.72% YoY), and the FY2017 full-year result was $1.9 million, up 80.72% from the prior year.
• Convertible Debt for Q4 2017 stood at $1.9 million, up from $1.1 million in the prior quarter.
• The five-year high for Convertible Debt was $1.9 million in Q4 2017, with the low at $60000.0 in Q4 2014.
• Historically, Convertible Debt has averaged $741132.4 across 4 years, with a median of $617908.0 in 2015.
• Annual changes were most pronounced in 2015 — Convertible Debt jumped 440.0% — and 2016, when it dropped 26.33%.
• Lineage Cell Therapeutics' Convertible Debt stood at $60000.0 in 2014, then jumped by 440.0% to $324000.0 in 2015, then jumped by 218.52% to $1.0 million in 2016, then surged by 80.72% to $1.9 million in 2017.
• The last three Convertible Debt figures came in at $1.9 million (Q4 2017), $1.1 million (Q1 2017), and $1.0 million (Q4 2016), per Business Quant data.